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SUMMARY
Objective We describe our experience of using the standard
application form, designed to streamline applications for multi-
centre research, to seek approval from all primary care
organizations (PCOs) in England and Wales to undertake a single
telephone interview with a health service manager.
Design We sent applications (n=316), by email to each PCO,
or consortium of PCOs, attaching a completed standard
application form, the 15 required documents, and the approval
we had been granted by the lead NHS organization. We
maintained detailed records of the responses to our application,
subsequent correspondence, additional paperwork requested,
and time spent on the approval process.
Setting The UK Research Governance Framework, which
regulates all research conducted in health and social care
settings.
Participants All PCOs in England and Wales.
Interventions None.
Main outcome measures Time taken to obtain approval to
undertake a telephone interview with a health service manager.
Results We were unable to establish contact with 13 (4%)
PCOs. Six months after submitting our application we had
received approval from 259/316 (82%) PCOs and were still
awaiting a verdict from 41 (13%). The median time to approval
was 56 days (IQR 42–72). Overall, an estimated 318 staff-hours
were spent completing supplementary forms, providing additional
information and chasing up dormant applications.
Conclusions Recent initiatives to ‘streamline’ research gov-
ernance approval have failed to address the problems that face
researchers undertaking multi-centre studies. There is an urgent
need to develop a simpler process that allows low risk research
to take place without threatening staff morale and endangering
the quality of the research outputs. In the meantime, we advise
researchers to allow far greater time than might reasonably be
envisioned to obtain research governance approval.
INTRODUCTION
Against a background of increasing global concern about
fraud and misconduct in medical research,1 the Department
of Health introduced a research governance framework in
2001 to regulate all research conducted in health and social
care settings.2,3 Official systems were introduced, embody-
ing a broad range of regulations, principles and standards of
good research practice that aimed to improve research
quality and accountability across all aspects of health care.
Responsibility for implementing the framework was
devolved to local primary care organizations (PCOs) and/
or hospital trusts. Organizations in England are encouraged
to collaborate within research and development (R&D)
consortia;4 similarly, in Wales, the Capricorn Research
Network grants R&D approval for all Welsh PCOs. An
‘information toolkit’ has been developed by the NHS R&D
Forum (http://www.rdforum.nhs.uk) which draws to-
gether practical examples of approval processes to assist
PCOs in meeting their research governance obligations.5
Recent literature on the R&D approval process has
reflected on the rationale behind research governance
procedures,1 explored how the governance process judges
the risk of harm within research6 and described the
underlying ethical principles,7,9 whilst arguing for flexibility
in the application of these principles to health care
research.6,7,10 While the justification for governance (‘to
ensure that the public can have confidence in, and benefit
from, quality research in health and social care’2) is clear,
several researchers have publicly expressed frustration and
demoralization resulting from stringent and lengthy
research governance procedures that impede the onset,
progress, quality and outcomes of research.11–16 In response
to these concerns, a standard R&D application form (Form
D) has recently been introduced to streamline applications
for multi-centre research which ‘all NHS organizations are
strongly recommended to accept.’17
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This paper is the first to describe the experience of using
the new ‘streamlined’ system to apply to all PCOs in
England and Wales for R&D approval for the initial phase of
an ethnographic study exploring respiratory workforce
dynamics in PCOs in England and Wales.18 This first phase
involved conducting a single telephone interview (max-
imum duration 45 minutes) with a health service manager in
a sample of PCOs with a range of demographic profiles and
offering diverse approaches to the delivery of respiratory
services. Our project schedule required us to complete
these interviews over three months, in preparation for
subsequent in-depth case studies of the development of
respiratory care in selected PCOs. Since approval was
sought simultaneously from all PCOs in England and Wales,
our experience provides a national snapshot of the current
state of obtaining governance approval for low-risk, multi-
centre research.
METHODS
Ethics approval and R&D approval from a lead
NHS organization
Ethics approval was granted on 8 December 2005, three
weeks in advance of the start of the study. We opted to
request governance approval from all 325 PCOs in England
and Wales so that we could establish a pool of PCOs from
which to sample organizations with a broad range of
geographic, demographic and service profiles. Following the
guidance on the R&D Forum website,19 we discussed our
application with a lead NHS organization, whose R&D
manager provided helpful advice and granted approval for
the nine PCOs within the local R&D consortium on 18
January 2006.
Approval from the 316 remaining PCOs in
England and Wales
During the week beginning 24 January 2006, we sent out
applications by email to 76 R&D leads covering 310 of the
remaining 316 PCOs in consortiums or individually, as
listed on the R&D Forum website for England and Wales.
No contact details were available for the R&D leads in the
other six PCOs. We attached a completed standard R&D
application form (Form D) and the 15 required documents
(Table 1). In addition, we appended the approval we had
been granted by the lead NHS organization.
Record of progress
The study researchers and secretary maintained detailed
records of the responses to our applications, subsequent
correspondence, and additional paperwork requested. Time
spent on the approval process was noted at the end of each
working day.
RESULTS
Initial responses
The first response arrived within a day, but the median time
for an initial response was 30 days (IQR 22–56). Of the 76
R&D leads contacted, 12 (16%) gave immediate approval
either by post or an email, another 12 (16%) acknowledged
receipt of the request for approval and provided a
timeframe within which they would respond once they
had spoken to the relevant committee. It transpired that a
further 12 (16%) of our applications had been sent to an
outdated or ‘out of office’ R&D contact and were then
redirected to the correct individuals. About a third (i.e. 27,
37%) requested further information on the study or had
specific requirements for their individual organizations. The
requests included queries relating to indemnity, funding,
sponsorship, supplementary forms specific to the PCO in
question (often duplicating information already provided),
XML versions of ethics and R&D forms, additional
curriculum vitae and requests for evidence of the peer
review process. Three of the Welsh PCOs asked us to
complete an alternative form on the Capricorn R&D
Network website. Ten R&D leads (13%) had still not
replied six months after the initial applications were sent
off.
PCO approval granted
The median time to gaining approval was 56 days (IQR 42–
72); three PCOs (1%) declined approval. By the end of July
2006 (i.e. six months after submitting our application) we 235
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Table 1 Documents accompanying the initial R&D approval
applications
Document
number
Description
1 NHS REC Application Form
2 NHS R&D Application Form
3 Scan of Signed R&D Form
4 Project Proposal
5 Project Flow Diagram
6 Screening Interview Topic Guide
7 Invitation Letter for Screening Interviews
8 Reminder 1 for Screening Interviews
9 Reminder 2 for Screening Interviews
10 Information Leaflet for Screening Interviews
11 Consent Form for Screening Interviews
12 Principal Investigator’s CV
13 Sponsor Confirmation
14 MREC Approval
15 Lead Organization’s R&D Approval
had received approvals from 259/316 PCOs (82%) across
England and Wales, although approval for 16 Welsh PCOs
was conditional on translating the information sheet and
consent form into Welsh. Time constraints have prevented
us from complying with this requirement and we have thus
lost the opportunity to gain potentially valuable insights into
respiratory service development in many of the Welsh
PCOs. We had been unable to contact 13 PCOs (4%) (six
without contact details, and seven because the details
provided were incorrect) and were still awaiting a verdict
from 41 (13%) after six months, by which time we had no
choice but to move on with subsequent phases of the study.
Time implications and opportunity costs
Overall, an estimated 318 staff-hours were spent achieving
R&D approval. This occupied all our secretarial time, a
substantial proportion of the senior researcher’s time and
considerable time input from the principal investigator over
about 10 weeks, as we were required to complete
supplementary forms, reformulate letters and chase up
dormant applications, rendering the study about two
months behind schedule (Figure 1). The on-going requests
for progress reports from the R&D offices, despite our
sending a standard report to all R&D offices from whom we
had had approval at six months, is currently further delaying
the project.
DISCUSSION
We have found that obtaining R&D approval for a very low
risk, multi-centre descriptive study involving NHS staff
remains, despite the new ‘streamlined’ R&D approval
procedure, an extremely cumbersome and time-consuming
process. Despite planning meticulously for this study and
undertaking a good deal of preparatory work before the
commencement of the project, these barriers to under-
taking the research, which are eminently avoidable, have
resulted in serious delays, threatened staff morale and
adversely impacted on the time for analysis, reviewing
literature and preparing for subsequent phases of the study.
Limitations and strengths of this work
The minimal intervention for which we sought approval
represented no foreseeable risk to participants, so our
findings may not be representative of the delays imposed by
the process on complicated intervention studies, and
particularly those involving patients. Also, our data only
relate to governance approval in England and Wales, and
these experiences may thus not be generalizable to Scotland
or Northern Ireland. The study’s main strength lies in the
fact that we attempted to approach all PCOs in England and
Wales either individually or through their R&D consortium.
Importantly, it is the first study to describe the experience
of using the ‘streamlined’ system.
Interpretation of findings in relation to the
published literature
Little appears to have changed since the introduction of a
standard R&D application form in March 2005 designed to
‘streamline the R&D approval process’ and ‘minimise
unnecessary bureaucracy for researchers.’17,20 The process
still feels impossibly cumbersome, taking a median of 56
days for 82% of PCOs to approve a short interview with a
health care manager. Our experience is very similar to that
reported before the introduction of the standard process. In
2003/04, only 80% of English PCOs had granted approval236
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Figure 1 Time taken to obtain R&D approvals from 259/316 PCOs
for a questionnaire survey of health care professionals after
four months.13 Another study involving patient ques-
tionnaires reported taking 103 days to achieve approval in
all the 20 NHS trusts to which they applied.14 A key factor
is the devolution of research governance to individual trusts
and a lack of central guidance, which has resulted in diverse
local interpretation and a plethora of different forms and
procedures.5 Although the standard application form is
‘strongly recommended’ by the R&D Forum, it is not
mandatory, and supplementary forms and procedures
abound. Six months after the introduction of the
‘streamlined’ procedures, a survey of PCO R&D officers
found that although they preferred their own local
documentation, they stated that they would accept the
standard application form.20 Our study, in which a third of
organizations requested additional forms or information,
suggests that this may not be the case.
Discussion papers have called for flexibility in estimating
risk and applying research governance procedures.6,7,10 Our
study, in which the nature of the research was harmless
enough to show the absurdity of stringent governance
requirements, illustrates this need. While it is clear that
staff involved in health research owe full accountability to
their study participants, governance procedures that have
developed in response to investigational medicinal products
cannot be appropriately applied to all applications for R&D
approval.
The NHS R&D Forum have just released a common
form for both local ethical and R&D approval which will
hopefully reduce the burden of form filling.21 However,
this does not address the key underlying problem of each
trust enforcing regulations according to their own particular
interpretation of the responsibilities. A system in which the
lead R&D department (or a ‘Multicentre R&D committee’)
classified research as being of high, medium or low risk
according to agreed criteria, so that local trusts would then
apply uniform regulations appropriate to the research,
would seem sensible. Timescales, such as apply to ethics
applications, should be mandatory.
CONCLUSIONS
Recent initiatives to ‘streamline’ research governance
approval have failed to address the problems that face
researchers undertaking multi-centre studies. There is an
urgent need for R&D departments, researchers and research
funders to cooperate in developing a simpler process that
allows low risk research to take place without threatening
the morale of staff and endangering the viability and quality
of the research project. The ‘bureaucracy busting’
intentions and plans for a research passport system as part
of the DoH ‘Best Research for Best Health’ strategy offer
some hope for the future.22 In the meantime, in the light of
our experience, we advise researchers to allow ample time
to obtain R&D approval and ask funding bodies to be
sympathetic to the associated unacceptable, but at present
unavoidable, delays and associated increased costs.
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